EA Newsletter

CatalystEA NewsletterDealsTEST
EA NewsletterEA Newsletter
The Biotech Sitting on a Fresh Launch and a Proven Pipeline Asset

The Biotech Sitting on a Fresh Launch and a Proven Pipeline Asset

A $17B specialty biotech just launched a brand-new drug in an underserved endocrine market, and early scripts are already tracking ahead of internal forecasts. On top of that, Phase 2 data for a first-in-class schizophrenia candidate already came back positive. The setup here is asymmetric.

EA NewsletterEA Newsletter
The Small-Cap Biotech Setting Up for a Second Act

The Small-Cap Biotech Setting Up for a Second Act

The market caught the rare-disease approval this spring. What it hasn't priced in is the second, third, and fourth act still building in the same pipeline. That's where the asymmetric setup lives.

EA NewsletterEA Newsletter
The $11 Billion Eye in the Sky That Every Government Wants a Piece Of

The $11 Billion Eye in the Sky That Every Government Wants a Piece Of

The geopolitical map is on fire, and one $11B name owns the map itself.

EA NewsletterEA Newsletter
The Picks-and-Shovels Play Catching a Wave of Bullish Options Flow

The Picks-and-Shovels Play Catching a Wave of Bullish Options Flow

Memory chips have run. The equipment makers that build those chips? They're sitting flat while institutional call buyers stack positions. One name is showing the kind of unusual options flow you don't ignore, and the AI capex wave hasn't fully washed onto its price action yet.

EA NewsletterEA Newsletter
A Battered SaaS Name Got a Major Bank Flip

A Battered SaaS Name Got a Major Bank Flip

A battered communication stock caught a major bank flip earlier this year, and the AI pivot story isn't priced in yet.

EA NewsletterEA Newsletter
The CRO Stock Just Rerated 47% Higher

The CRO Stock Just Rerated 47% Higher

Two Wall Street upgrades just put a beaten-down healthcare name back on the map.

EA NewsletterEA Newsletter
The Pick-and-Shovel GLP-1 Stock the Street Is Still Sleeping On

The Pick-and-Shovel GLP-1 Stock the Street Is Still Sleeping On

The boring packaging play quietly cashing in on the weight-loss gold rush.

EA NewsletterEA Newsletter
The AI Picks-and-Shovels Play That Just Got a 25% Target Hike

The AI Picks-and-Shovels Play That Just Got a 25% Target Hike

When Wall Street raises a price target by $28 in a single morning, the model usually just caught up to a reality the market hasn't priced in yet.

EA NewsletterEA Newsletter
Two Upgrades, One Sleepy Chart, and a 32% Gap to Close

Two Upgrades, One Sleepy Chart, and a 32% Gap to Close

Two analysts quietly raised the bar on this auto play—one sees 32% room to run.

EA NewsletterEA Newsletter
The Insurance Heavyweight Coiled Just Below a Breakout

The Insurance Heavyweight Coiled Just Below a Breakout

For weeks now, the market's been all about chips and AI. Look one aisle over, and financials, especially the P&C insurers, are setting up the kind of base-and-break pattern that historically pays well.

EA NewsletterEA Newsletter
The Mid-Cap Industrial That Just Got the Sell-Side Spotlight

The Mid-Cap Industrial That Just Got the Sell-Side Spotlight

This infrastructure materials name beat Q1 estimates across every segment, and the multiple has barely moved. Here’s why the gap between price and value is still wide open.

EA NewsletterEA Newsletter
The Travel Stock That's One Push Away From Breaking Out

The Travel Stock That's One Push Away From Breaking Out

A truce was inked, oil cracked 2%—one hotel giant could ride the next leg up